Drugs / MVA-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01923610 | Sep 2013 → Sep 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-B | “an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and...” PMID 29065142 ↗ Oct 2017 |
| Modality | Vaccine | “an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B)” PMID 29065142 ↗ Oct 2017 |
| Route | Intramuscular | “receive 3 intramuscular injections of MVA-B at weeks 0, 4 and 16” NCT01923610 ↗ |